Methylation inhibitor therapy in the treatment of myelodysplastic syndrome (original) (raw)
Gore S (2004) Classification, treatment goals, and management principles for myelodysplastic syndromes. Cancer Control11 (Suppl 6): 3–6 ArticlePubMed Google Scholar
Bennett JM et al. (1976) Proposals for the classification of the acute leukaemias: French–American–British (FAB) cooperative group. Br J Haematol33: 451–458 ArticleCASPubMed Google Scholar
Bennett JM et al. (1982) Proposals for the classifications of myelodysplastic syndromes. Br J Haematol51: 189–199 ArticleCASPubMed Google Scholar
Bennett JM et al. (1985) Proposed revised criteria for the classification of acute myeloid leukemia: a report of the French-American-British Cooperative Group. Ann Intern Med103: 620–625 ArticleCASPubMed Google Scholar
Bennett JM (2000) World Health Organization classficiation of the acute leukemias and myelodysplastic syndrome. Int J Hematol72: 131–133 CASPubMed Google Scholar
Greenberg et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndrome. Blood89: 2079–2088 ArticleCASPubMed Google Scholar
Stone R (2004) Treatment options for myelodysplastic syndromes. Cancer Control11 (Suppl 6): 7–10 ArticlePubMed Google Scholar
List A (2004) Methyltransferase inhibitors: changing the treatment algorithm for myelodysplastic syndromes. Cancer Control11 (Suppl 6): 16–19 ArticlePubMed Google Scholar
Herman JG and Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med349: 2042–2054 ArticleCASPubMed Google Scholar
Kaminskas E et al. (2005) FDA drug approval summary: azacidine (azacitidine™) for injectable suspension. Oncologist10: 176–182 ArticleCASPubMed Google Scholar
Kaminskas E et al. (2005) Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res11: 3604–3608 ArticleCASPubMed Google Scholar
Silverman LR et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol20: 2429–2440 ArticleCASPubMed Google Scholar
Rüter B et al. (2005) Re-treatment results in second remission of MDS with previous response to low-dose 5-aza-2′-doxycytidine (Decitabine). Leuk Res29 (Suppl): S65 Article Google Scholar
O' Brien S et al. (2005) Decitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules [abstract]. J Clin Oncol23: 6545 Article Google Scholar
Wijermans P et al. (2000) Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol18: 956–962 ArticleCASPubMed Google Scholar
Garcia-Manero G et al. (2005) Results of a phase I/II study of the combination of 5-aza-2′-deoxycitidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome [abstract]. J Clin Oncol23: 6544. Article Google Scholar
Saba HI et al. (2005) Clinical benefit and survival endpoints from a phase III trial comparing decitabine (DAC) vs. supportive care (SC) in patients with advanced myelodysplastic syndromes (MDS) [abstract]. J Clin Oncol23: 6543 Article Google Scholar
Burchenal JH and Carter SK (1972) New cancer chemotherapeutic agents. Cancer30: 1639–1646 ArticlePubMed Google Scholar
Massimo L and Comelli A (1975) New drugs for the therapy of acute leukemia. Minerva Med66: 2568–2576 PubMed Google Scholar
Silverman LR et al. (1993) Effects of treatment with azacitidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia7 (Suppl 1): 21–29 PubMed Google Scholar
Silverman LR (2001) Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist6 (Suppl 5): 8–14 ArticleCASPubMed Google Scholar
Marcucci G et al. (2005) Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol45: 597–603 ArticleCASPubMed Google Scholar
Kornblith AB et al. (2002) Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol20: 2441–2452 ArticleCASPubMed Google Scholar
Najfeld V et al. (2004) The modulating effect of azacitidine (Aza C) on the cytogenetically tracked MDS clone impact survival [abstract]. Blood104: 1429 Article Google Scholar
Kantarjian HM et al. (1997) Decitabine studies in chronic and acute myelogenous leukemia. Leukemia11 (Suppl 1): S35–S36 PubMed Google Scholar
Kantarjian HM et al. (2003) Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer98: 522–528 ArticleCASPubMed Google Scholar
Pinto A and Zagonel V (1993) 5-Aza-2′-deoxycytidine (decitabine) and azacitidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia7 (Suppl 1): 51–60 PubMed Google Scholar
Issa JP et al. (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood103: 1635–1640 ArticleCASPubMed Google Scholar
Aparicio A and Weber JS (2002) Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors. Curr Opin Investig Drugs3: 627–633 PubMed Google Scholar
Goffin J and Eisenhauer E (2002) DNA methyltransferase inhibitors — state of the art. Ann Oncol13: 1699–1716 ArticlePubMed Google Scholar
Cheson BD et al. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood96: 3671–3674 CASPubMed Google Scholar
Cutler CS et al. (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood104: 579–585 ArticleCASPubMed Google Scholar
Williamson PJ et al. (1994) Establishing the incidence of myelodysplastic syndrome. Br J Haematol87: 743–745 ArticleCASPubMed Google Scholar
Ho AY et al. (2004) Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood104: 1616–1623 ArticleCASPubMed Google Scholar
Christman JK (2002) azacitidine and 5-aza-2'-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene21: 5483–5495 ArticleCASPubMed Google Scholar
Garcia-Manero G et al. (2002) DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res8: 2217–2224 CASPubMed Google Scholar
Rudek MA et al. (2005) Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol23: 3906–3911 ArticleCASPubMed Google Scholar